Literature DB >> 2345465

Effects of calcium antagonists on anti-cancer drug toxicity to haematopoietic progenitor cells in normal human bone marrow.

T Nakarai1, S Koizumi.   

Abstract

Calcium (Ca) antagonists are promising candidates to enhance the drug sensitivity of resistant tumor cells. However, it is not yet clear whether these agents increase anti-cancer drug toxicity to normal human haematopoietic progenitor cells. In this paper, we examined the ability of Ca antagonists including verapamil, diltiazem, nicardipine, and clomipramine, to augment the toxicity of vincristine (VCR) and adriamycin (ADM) to normal bone marrow granulocyte-macrophage progenitor cells (CFU-GM) in vitro. When CFU-GM colonies were cultured for 10 days with VCR(10(-9) M) or ADM(10(-8) M) alone, the number of colonies was reduced to 73.7% +/- 13.0% (mean +/- S.D., n = 9) and 63.4% +/- 10.2% (n = 9) of those of the controls, respectively. The addition of Ca antagonists at the clinically achievable concentrations of 0.2 and 2 microM further enhanced the toxicity of these drugs; verapamil even at a lower concentration reduced the colony number to 36.8% +/- 8.9% (n = 4) for VCR and 32.8% +/- 9.5% (n = 4) for ADM. Nicardipine also reduced CFU-GM to a lesser degree in co-culture with ADM. Ca antagonists alone did not suppress CFU-GM. No enhancement of toxicity was mediated by Ca antagonists at lower VCR or ADM concentrations (10(-10) M or less). In addition, after a short-term (24 h) co-incubation of VCR or ADM with Ca antagonists, no significant enhancement of toxicity was observed. These results indicated that the combination of VCR or ADM with Ca antagonists may enhance toxicity to normal human CFU-GM under certain circumstances.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2345465     DOI: 10.1016/0145-2126(90)90025-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

1.  Comparative effects of racemic verapamil vs R-verapamil on normal and leukemic progenitors.

Authors:  G Visani; M Fogli; P Tosi; E Ottaviani; B Gamberi; A Cenacchi; S Manfroi; S Tura
Journal:  Ann Hematol       Date:  1993-06       Impact factor: 3.673

2.  Phase I and pharmacokinetic study of D-verapamil and doxorubicin.

Authors:  D Bissett; D J Kerr; J Cassidy; P Meredith; U Traugott; S B Kaye
Journal:  Br J Cancer       Date:  1991-12       Impact factor: 7.640

3.  Reversal of methotrexate cytotoxicity to human bone marrow cells and leukemic K562 cells by leucovorin: methotrexate polyglutamates formation as a possible important factor.

Authors:  S Koizumi; Y Ueno; I Ohno; T Ichihara; Y Tamaru; H Matsukawa
Journal:  Jpn J Cancer Res       Date:  1990-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.